- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple sclerosis
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 934KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 66KB)
Glatiramer acetate – March 2021
Glatiramer: Injection containing glatiramer acetate 20 mg in 1 mL single dose pre-filled syringe; Injection containing glatiramer acetate 40 mg in 1 mL single dose pre-filled syringe; Glatira®
Last updated
2 July 2021